The GBA Multimodal Study in Parkinson's Disease
Recruiting · NCT04101968 · Observational (researchers observe without assigning treatment) · Lead sponsor: Pacific Parkinson's Research Centre
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.
Who can take part
Inclusion criteria
- heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
- age 18 to 80 years.
Exclusion criteria
- co-occurrence of other neurological disorders;
- implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
- severe claustrophobia;
- intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
- ongoing treatment with cholinergic drugs
Where it is running
3 locations listed across 2 US states.
- Oregon Health & Science University - Portland, Oregon, United States
- University of Washington - Seattle, Washington, United States
- Pacific Parkinson's Research Centre | University of British Columbia - Vancouver, British Columbia, Canada